Research Progress of Protective Effect of Drug Therapy on Fertility in Female Patients with Lymphoma

Abstract

Lymphoma is a common hematological malignancy in young population. During the treatment of lymphoma, the gonadal damage caused by chemotherapy cannot be ignored for the reverse impact on the reproductive function of the patients during survivorship. As the survival period of lymphoma patients has increasingly extended, fertility preservation is now a hot topic. Fertility preservation methods for female patients currently include embryo cryopreservation, oocyte cryopreservation, ovarian tissue cryopreservation, pharmacological protection therapy, etc. Among them, pharmacological protection therapy has a wide range of applications thanks to its cheapness and easy implementation. It is based on the use of gonadal function-related hormone analogues, including gonadotropin-releasing hormone agonists and antagonists, with the effort to slow down the progression of premature ovarian failure and thus preserve the long-term reproductive potential. Although most studies suggest that it has a clear reproductive protective effect, there are still some research results that hold different opinions, especially for high-risk patients requiring hematopoietic stem cell transplantation. This article aims to summarize the current status of clinical application of drug reproductive protection therapy and provide ideas for long-term reproductive protection for lymphoma patients with reproductive needs.